Is CRON or DMRA more profitable?

CRON runs the higher net margin — CRON at 30.98% versus DMRA at 0.00%.

How have CRON and DMRA total returns compared?

Over the past 5 years, CRON delivered -9.92% and DMRA delivered -25.05% annualized total return. Past performance doesn't predict future results.

Cronos Group Inc. (CRON) vs Damora Therapeutics, Inc. (DMRA)

A side-by-side comparison of Cronos Group Inc. and Damora Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CRON

Cronos Group Inc.

$1.21B

$3.25HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

DMRA

Damora Therapeutics, Inc.

$1.24B

$20.22HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — CRON vs DMRA

growth of $100 · dividends reinvested · last 6y

CRON -40.6% (-8.3%/yr)DMRA -94.6% (-38.5%/yr)CRON compounded faster over this window

Log scale — wide-divergence pair

CRON DMRA

CRON vs DMRA: by the numbers

•DMRA is the larger company ($1.24B vs $1.21B market cap).
•CRON is profitable (30.98% net margin) while DMRA runs a net loss (0.00%).

Metrics side by side

Valuation

Metric	CRON	DMRA
P/E ratio	17.95	N/A
P/S ratio	5.39	N/A
P/B ratio	1.14	3.22
EV / EBITDA	27.60	N/A
FCF yield	4.09%	N/A

Profitability

Metric	CRON	DMRA
Gross margin	36.16%	0.00%
Operating margin	-11.96%	0.00%
Net margin	30.98%	0.00%
ROE	6.53%	-50.93%
ROIC	1.12%	-52.44%

Growth (annualized)

Metric	CRON	DMRA
Revenue CAGR (5Y)	31.80%	N/A
Total return CAGR (5Y)	-9.92%	-25.05%

Frequently asked

Is CRON or DMRA more profitable?: CRON runs the higher net margin — CRON at 30.98% versus DMRA at 0.00%.
How have CRON and DMRA total returns compared?: Over the past 5 years, CRON delivered -9.92% and DMRA delivered -25.05% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CRON analysis Full DMRA analysis Interactive comparison tool

Dig into the metrics

Cronos P/E ratio Cronos ROE Damora Therapeutics ROE Cronos operating margin Damora Therapeutics operating margin Cronos revenue growth Damora Therapeutics revenue growth Cronos free cash flow Damora Therapeutics free cash flow

Cronos & Damora Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.